Related Experiment Video
Updated: Jun 5, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications
Matthew J Damasiewicz1, Nigel D Toussaint, Kevan R Polkinghorne
1Department of Nephrology, Monash Medical Centre, Monash University, Clayton, Victoria, Australia. Matthew.Damasiewicz@monash.edu
Abstract:
Fibroblast growth factor 23 (FGF-23) is a recently discovered regulator of phosphate and mineral metabolism. Its main physiological function is the enhancement of renal phosphate excretion. FGF-23 levels are inversely related to renal function and in patients with chronic kidney disease (CKD) elevation in FGF-23 precedes the rise of serum phosphate. Studies have demonstrated an important role for FGF-23 in the development of secondary hyperparathyroidism through an effect on parathyroid hormone and calcitriol. In cross-sectional studies FGF-23 has been associated with surrogate markers of cardiovascular disease such as endothelial dysfunction and arterial stiffness. FGF-23 has also been associated with both progression of CKD and mortality in dialysis patients. The discovery of FGF-23 has provided a profound new insight into bone and mineral metabolism, and it may become an important biomarker and therapeutic target in CKD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Acute Kidney Injury II: Pathophysiology
Diabetic Nephropathy
Acute Kidney Injury IV: Diagnostic Studies and Prevention

